Matches in SemOpenAlex for { <https://semopenalex.org/work/W4230874141> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4230874141 abstract "Abstract Background: Circulating tumor cells (CTCs) are non-invasive biomarkers that could be used to characterize changes in tumors. In this study, we monitored the number of CTCs, as well as the BRAF genotype of individual CTCs. Methods: CTCs were isolated from peripheral blood using a high-density dielectrophoretic microwell array, followed by labeling with melanoma-specific markers (MART-1 and/or gp100) and a leukocyte marker (CD45). Results: Examination of patients with stage 0–III melanoma detected CTCs even in patients with early disease (stage 0 or I). Next, we analyzed CTCs in five patients with stage IV melanoma during treatment with BRAF/MEK inhibitors. The number of CTCs fluctuated in association with the drug response in four of the five patients, suggesting that the total number of CTCs usually reflected the drug response. Interestingly, one of those patients had CTCs with seven different BRAF genotypes, and the mutated CTCs disappeared upon treatment with BRAF/MEK inhibitors, except for those harboring BRAF A598V . Conclusions: CTCs are present even in the early stage of melanoma, and the number of CTCs seems to reflect drug response during treatment with BRAF/MEK inhibitors. Furthermore, genetic heterogeneity of BRAF may contribute to drug resistance of BRAF/MEK inhibitor. Our findings demonstrate the usefulness of CTC analysis in melanoma for monitoring targeted therapies and understanding mechanism of drug resistance." @default.
- W4230874141 created "2022-05-11" @default.
- W4230874141 creator A5004285661 @default.
- W4230874141 creator A5006212543 @default.
- W4230874141 creator A5042541348 @default.
- W4230874141 creator A5061454283 @default.
- W4230874141 creator A5064744956 @default.
- W4230874141 creator A5084323300 @default.
- W4230874141 creator A5090126993 @default.
- W4230874141 date "2020-10-09" @default.
- W4230874141 modified "2023-09-28" @default.
- W4230874141 title "Usefulness of Monitoring Circulating Tumor Cells as a Therapeutic Biomarker in Melanoma with BRAF Mutation" @default.
- W4230874141 doi "https://doi.org/10.21203/rs.3.rs-88937/v1" @default.
- W4230874141 hasPublicationYear "2020" @default.
- W4230874141 type Work @default.
- W4230874141 citedByCount "0" @default.
- W4230874141 crossrefType "posted-content" @default.
- W4230874141 hasAuthorship W4230874141A5004285661 @default.
- W4230874141 hasAuthorship W4230874141A5006212543 @default.
- W4230874141 hasAuthorship W4230874141A5042541348 @default.
- W4230874141 hasAuthorship W4230874141A5061454283 @default.
- W4230874141 hasAuthorship W4230874141A5064744956 @default.
- W4230874141 hasAuthorship W4230874141A5084323300 @default.
- W4230874141 hasAuthorship W4230874141A5090126993 @default.
- W4230874141 hasBestOaLocation W42308741411 @default.
- W4230874141 hasConcept C114851261 @default.
- W4230874141 hasConcept C121608353 @default.
- W4230874141 hasConcept C126322002 @default.
- W4230874141 hasConcept C143998085 @default.
- W4230874141 hasConcept C146357865 @default.
- W4230874141 hasConcept C151730666 @default.
- W4230874141 hasConcept C184235292 @default.
- W4230874141 hasConcept C2777658100 @default.
- W4230874141 hasConcept C2779013556 @default.
- W4230874141 hasConcept C2781197716 @default.
- W4230874141 hasConcept C2781249067 @default.
- W4230874141 hasConcept C502942594 @default.
- W4230874141 hasConcept C55493867 @default.
- W4230874141 hasConcept C57074206 @default.
- W4230874141 hasConcept C61238886 @default.
- W4230874141 hasConcept C71924100 @default.
- W4230874141 hasConcept C86803240 @default.
- W4230874141 hasConcept C89423630 @default.
- W4230874141 hasConcept C95444343 @default.
- W4230874141 hasConceptScore W4230874141C114851261 @default.
- W4230874141 hasConceptScore W4230874141C121608353 @default.
- W4230874141 hasConceptScore W4230874141C126322002 @default.
- W4230874141 hasConceptScore W4230874141C143998085 @default.
- W4230874141 hasConceptScore W4230874141C146357865 @default.
- W4230874141 hasConceptScore W4230874141C151730666 @default.
- W4230874141 hasConceptScore W4230874141C184235292 @default.
- W4230874141 hasConceptScore W4230874141C2777658100 @default.
- W4230874141 hasConceptScore W4230874141C2779013556 @default.
- W4230874141 hasConceptScore W4230874141C2781197716 @default.
- W4230874141 hasConceptScore W4230874141C2781249067 @default.
- W4230874141 hasConceptScore W4230874141C502942594 @default.
- W4230874141 hasConceptScore W4230874141C55493867 @default.
- W4230874141 hasConceptScore W4230874141C57074206 @default.
- W4230874141 hasConceptScore W4230874141C61238886 @default.
- W4230874141 hasConceptScore W4230874141C71924100 @default.
- W4230874141 hasConceptScore W4230874141C86803240 @default.
- W4230874141 hasConceptScore W4230874141C89423630 @default.
- W4230874141 hasConceptScore W4230874141C95444343 @default.
- W4230874141 hasLocation W42308741411 @default.
- W4230874141 hasLocation W42308741412 @default.
- W4230874141 hasOpenAccess W4230874141 @default.
- W4230874141 hasPrimaryLocation W42308741411 @default.
- W4230874141 hasRelatedWork W10138567 @default.
- W4230874141 hasRelatedWork W11779430 @default.
- W4230874141 hasRelatedWork W14781274 @default.
- W4230874141 hasRelatedWork W20837101 @default.
- W4230874141 hasRelatedWork W2090429 @default.
- W4230874141 hasRelatedWork W3320906 @default.
- W4230874141 hasRelatedWork W7207526 @default.
- W4230874141 hasRelatedWork W7286834 @default.
- W4230874141 hasRelatedWork W8167168 @default.
- W4230874141 hasRelatedWork W8724660 @default.
- W4230874141 isParatext "false" @default.
- W4230874141 isRetracted "false" @default.
- W4230874141 workType "article" @default.